Cullinan Oncology - Raised $380M Funding from 19 investors

Nov 8, 2024 · Cullinan Oncology has raised a total funding of $380M over 3 rounds from 19 investors. Investors include Venrock, Foresite Capital and 17 others. Their latest funding round …

CouponFollow Extension

$380
OFF

Cullinan Oncology - Raised $380M Funding From 19 Investors

2 days from now

Nov 8, 2024 · Cullinan Oncology has raised a total funding of $380M over 3 rounds from 19 investors. Investors include Venrock, Foresite Capital and 17 others. Their latest funding round …

tracxn.com

$380
OFF

Cullinan Oncology - Company Profile - Tracxn

2 days from now

Oct 22, 2024 · Cullinan Oncology - Developer of small molecule and vaccine therapeutics for cancer and immunology disorders. Public Company. Raised a total funding of $380M over 3 …

tracxn.com

$280
OFF

Cullinan Therapeutics, Inc. Announces Oversubscribed $280

2 days from now

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company …

massbio.org

$131200000
OFF

Series C - Cullinan Oncology - 2020-12-17 - Crunchbase

2 days from now

Cullinan Oncology raised $131200000 on 2020-12-17 in Series C. Start Free Trial . Chrome Extension

crunchbase.com

$456
OFF

Cullinan Oncology Provides Corporate Update And Reports …

2 days from now

Aug 10, 2021 · Strong balance sheet with cash and investments of $456.3 million as of June 30, 2021. CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. …

yahoo.com

$131
OFF

Cullinan Oncology Completes $131.2 Million Series C Financing

2 days from now

Dec 17, 2020 · Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative …

biospace.com

$78
OFF

Cullinan Oncology Competitors And Alternatives - Tracxn

2 days from now

Oct 22, 2024 · Cullinan Oncology's competitors have raised a total of $78.6B funding across 3338 funding rounds. See the distribution of funded competitors of Cullinan Oncology below. Total …

tracxn.com

$280
OFF

Cullinan Therapeutics - Crunchbase Company Profile & Funding

2 days from now

Cullinan Therapeutics raised $280 million in a private placement to target the autoimmune market. Additionally, the company announced the appointment of a new Chief Financial Officer. ...

crunchbase.com

FAQs about Cullinan Oncology - Raised $380M Funding from 19 investors Coupon?

How many investors does Cullinan oncology have?

Cullinan Oncology has 17 investors including Foresite Capital and BVF Partners. How much funding has Cullinan Oncology raised to date? Cullinan Oncology has raised $389.7M. When was the last funding round for Cullinan Oncology? Cullinan Oncology closed its last funding round on Mar 31, 2022 from a Post-IPO Equity round. ...

How much money has Cullinan Oncology raised?

Cullinan Oncology has raised $389.7M. When was the last funding round for Cullinan Oncology? Cullinan Oncology closed its last funding round on Mar 31, 2022 from a Post-IPO Equity round. Who are Cullinan Oncology 's competitors? ...

Will Cullinan provide clinical data updates on targeted oncology programs?

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 ...

When did Cullinan oncology close?

Cullinan Oncology closed its last funding round on Mar 31, 2022 from a Post-IPO Equity round. Who are Cullinan Oncology 's competitors? Alternatives and possible competitors to Cullinan Oncology may include Ribon Therapeutics , Sirnaomics , and Cyteir Therapeutics. ...

Where is Cullinan oncology located?

Cullinan Oncology is located in Cambridge, Massachusetts, United States. Who invested in Cullinan Oncology? Cullinan Oncology has 17 investors including Foresite Capital and BVF Partners. How much funding has Cullinan Oncology raised to date? ...

What is Cullinan oncology?

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2023. ...